LAG3 and neoplasm: Consistently, EZH2i promoted T cells activation (Granzyme B, IFNγ) and inhibited their exhaustion (LAG3) in tumor treated with chemotherapy (Fig. 6F, G), with similar phenomena as chemoimmunotherapy (Figure S5G).